title: Effect of spergualin in autoimmune disease mice.
abstract: We investigated the effect of spergualin (SGL) upon the development of spontaneous systemic lupus erythematosus-like lesions in male MRL/MpJ-lpr/lpr mice. SGL was administered ip at doses of 2.5, 5 and 10 mg/kg to two groups of mice. One group received SGL prophylactically from 7 to 21 weeks of age. The other group received SGL curatively from 13 to 27 weeks of age. The occurrence of lupus lesions was characterized by enlarged lymphoid organs, high anti-DNA titer and blood urea nitrogen, and severe glomerular nephritis. In both groups these characteristics were significantly suppressed by SGL in a dose-dependent manner. This inhibitory activity was greatest at a dose of 10 mg/kg. These findings suggest that SGL has prophylactic and curative effects against lupus lesions in autoimmune disease in mice.
authors: Research Laboratories, Nippon Kayaku Co., Ltd., Tokyo, Japan.
authors: K
authors: K
authors: Nemoto
authors: M
authors: M
authors: Hayashi
authors: J
authors: J
authors: Ito
authors: F
authors: F
authors: Abe
authors: T
authors: T
authors: Takita
authors: T
authors: T
authors: Nakamura
authors: T
authors: T
authors: Takeuchi
authors: H
authors: H
authors: Umezawa
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004247:DNA / Q000276:immunology; D006146:Guanidines / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008297:Male; D051379:Mice
chemical_list: D000903:Antibiotics, Antineoplastic; D006146:Guanidines; D007166:Immunosuppressive Agents; C033797:spergualin; D004247:DNA